202 related articles for article (PubMed ID: 15906071)
1. "Melanoma inhibitory activity" (MIA): a promising serological tumour marker in metastatic uveal melanoma.
Reiniger IW; Schaller UC; Haritoglou C; Hein R; Bosserhoff AK; Kampik A; Mueller AJ
Graefes Arch Clin Exp Ophthalmol; 2005 Nov; 243(11):1161-6. PubMed ID: 15906071
[TBL] [Abstract][Full Text] [Related]
2. Melanoma inhibitory activity: a novel serum marker for uveal melanoma.
Schaller UC; Bosserhoff AK; Neubauer AS; Buettner R; Kampik A; Mueller AJ
Melanoma Res; 2002 Dec; 12(6):593-9. PubMed ID: 12459649
[TBL] [Abstract][Full Text] [Related]
3. Osteopontin and 'melanoma inhibitory activity': comparison of two serological tumor markers in metastatic uveal melanoma patients.
Haritoglou I; Wolf A; Maier T; Haritoglou C; Hein R; Schaller UC
Ophthalmologica; 2009; 223(4):239-43. PubMed ID: 19270465
[TBL] [Abstract][Full Text] [Related]
4. [Melanoma inhibitory activity (MIA). Evaluation of a new tumor-associated antigen as a serum marker for uveal melanomas].
Schaller UC; Mueller AJ; Bosserhoff AK; Haraida S; Löhrs U; Buettner R; Kampik A
Ophthalmologe; 2000 Jun; 97(6):429-32. PubMed ID: 10916387
[TBL] [Abstract][Full Text] [Related]
5. S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening. A comparison with liver function tests.
Missotten GS; Korse CM; van Dehn C; Linders TC; Keunen JE; Jager MJ; Bonfrer JM
Tumour Biol; 2007; 28(2):63-9. PubMed ID: 17264538
[TBL] [Abstract][Full Text] [Related]
6. Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study.
Kadkol SS; Lin AY; Barak V; Kalickman I; Leach L; Valyi-Nagy K; Majumdar D; Setty S; Maniotis AJ; Folberg R; Pe'er J
Invest Ophthalmol Vis Sci; 2006 Mar; 47(3):802-6. PubMed ID: 16505010
[TBL] [Abstract][Full Text] [Related]
7. Serum markers to detect metastatic uveal melanoma.
Barak V; Frenkel S; Kalickman I; Maniotis AJ; Folberg R; Pe'er J
Anticancer Res; 2007; 27(4A):1897-900. PubMed ID: 17649791
[TBL] [Abstract][Full Text] [Related]
8. Trends in liver function tests: a comparison with serum tumor markers in metastatic uveal melanoma (part 2).
Hendler K; Pe'er J; Kaiserman I; Baruch R; Kalickman I; Barak V; Frenkel S
Anticancer Res; 2011 Jan; 31(1):351-7. PubMed ID: 21273623
[TBL] [Abstract][Full Text] [Related]
9. Osteopontin as a serologic marker for metastatic uveal melanoma: results of a pilot study.
Reiniger IW; Wolf A; Welge-Lüssen U; Mueller AJ; Kampik A; Schaller UC
Am J Ophthalmol; 2007 Apr; 143(4):705-7. PubMed ID: 17386288
[TBL] [Abstract][Full Text] [Related]
10. Receiver operating characteristic analysis: calculation for the marker 'melanoma inhibitory activity' in metastatic uveal melanoma patients.
Klingenstein A; Haritoglou I; Schaumberger MM; Nentwich MM; Hein R; Schaller UC
Melanoma Res; 2011 Aug; 21(4):352-6. PubMed ID: 21540751
[TBL] [Abstract][Full Text] [Related]
11. The dynamics of serum tumor markers in predicting metastatic uveal melanoma (part 1).
Barak V; Kaiserman I; Frenkel S; Hendler K; Kalickman I; Pe'er J
Anticancer Res; 2011 Jan; 31(1):345-9. PubMed ID: 21273622
[TBL] [Abstract][Full Text] [Related]
12. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
[TBL] [Abstract][Full Text] [Related]
13. VEGF as a biomarker for metastatic uveal melanoma in humans.
Barak V; Pe'er J; Kalickman I; Frenkel S
Curr Eye Res; 2011 Apr; 36(4):386-90. PubMed ID: 21284506
[TBL] [Abstract][Full Text] [Related]
14. Melanoma inhibitory activity (MIA) as a serum marker for early detection of post-surgical relapse in melanoma patients: comparison with 5-S-cysteinyldopa.
Matsushita Y; Hatta N; Wakamatsu K; Takehara K; Ito S; Takata M
Melanoma Res; 2002 Aug; 12(4):319-23. PubMed ID: 12170180
[TBL] [Abstract][Full Text] [Related]
15. [Protein S100 beta and Melanoma Inhibitory Activity (MIA): a prospective study of their clinical value for the early detection of metastasis in malignant melanoma].
Loppin M; Quillien V; Adamski H; Ollivier I; Garlantézec R; Chevrant-Breton J
Ann Dermatol Venereol; 2007; 134(6-7):535-40. PubMed ID: 17657179
[TBL] [Abstract][Full Text] [Related]
16. Melanoma inhibitory activity (MIA), a serological marker of malignant melanoma.
Bosserhoff AK; Dreau D; Hein R; Landthaler M; Holder WD; Buettner R
Recent Results Cancer Res; 2001; 158():158-68. PubMed ID: 11092043
[TBL] [Abstract][Full Text] [Related]
17. Potential Role of Soluble c-Met as a New Candidate Biomarker of Metastatic Uveal Melanoma.
Barisione G; Fabbi M; Gino A; Queirolo P; Orgiano L; Spano L; Picasso V; Pfeffer U; Mosci C; Jager MJ; Ferrini S; Gangemi R
JAMA Ophthalmol; 2015 Sep; 133(9):1013-21. PubMed ID: 26068448
[TBL] [Abstract][Full Text] [Related]
18. Using the direct-injection model of early uveal melanoma hepatic metastasis to identify TPS as a potentially useful serum biomarker.
Barak V; Frenkel S; Valyi-Nagy K; Leach L; Apushkin MA; Lin AY; Kalickman I; Baumann NA; Pe'er J; Maniotis AJ; Folberg R
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4399-402. PubMed ID: 17898257
[TBL] [Abstract][Full Text] [Related]
19. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
[TBL] [Abstract][Full Text] [Related]
20. Impact of lymph node metastases on serum level of melanoma inhibitory activity in stage III melanoma patients.
Hofmann MA; Schicke B; Fritsch A; Biesold S; Gussmann F; Küchler I; Voit C; Trefzer U
J Dermatol; 2011 Sep; 38(9):880-6. PubMed ID: 21658116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
